최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기소아청소년정신의학 = Journal of the Korean Academy of Child and Adolescent Psychiatry, v.25 no.2, 2014년, pp.82 - 88
송정은 (국민건강보험 일산병원 정신건강의학과) , 홍현주 (한림대학교 의과대학 정신건강의학교실) , 이병욱 (국민건강보험 일산병원 정신건강의학과) , 육기환 (CHA의과학대학교 분당차병원 정신건강의학교실)
Objectives : The aim of our study was to investigate association of norepinephrine transporter gene (SLC6A2) polymorphism and side effects of osmotic-release oral system methylphenidate (OROS MPH) in children with attention-deficit hyperactivity disorder (ADHD). Methods : We recruited drug naive chi...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
ADHD의 약물치료로 사용되는 OROS MPH의 부작용은 무엇인가? | 9%가 심각한 부작용을 경험하였다.6) 오로스 메칠페니데이트(osmotic-release oral system methylphenidate,OROS MPH)의 비교적 흔한 부작용으로는 식욕부진, 불면, 두통, 복통 등이 있다.7,8) OROS MPH를 복용한 569명의 ADHD 아동을 대상으로 한 국내 다기관 관찰 연구에서도 20. | |
주의력결핍 과잉행동장애란 무엇인가? | 주의력결핍 과잉행동장애(attention-deficit hyperactivity disorder, ADHD)는 과잉행동, 충동성, 부주의를 임상적 특징으로 하며, 전 세계 유병률이 5.29%1)로 보고된 소아정신과 질환이다. 메칠페니데이트(methylphenidate)는 ADHD 치료의 첫번째 선택 약물로서 널리 사용되고 있으며 65-75%의 치료반응률을 보이는 것으로 알려져 있다. | |
ADHD 치료의 첫번째 선택 약물은 무엇인가? | 29%1)로 보고된 소아정신과 질환이다. 메칠페니데이트(methylphenidate)는 ADHD 치료의 첫번째 선택 약물로서 널리 사용되고 있으며 65-75%의 치료반응률을 보이는 것으로 알려져 있다.2) 이러한 메칠페니데이트의 우수한 치료 효과에도 불구하고 ADHD 치료 약물의 중단, 혹은 비순응은 13. |
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-948.
Vaughan B, Kratochvil CJ. Pharmacotherapy of pediatric attentiondeficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2012;21:941-955.
Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med 2010;122:184-191.
Toomey SL, Sox CM, Rusinak D, Finkelstein JA. Why do children with ADHD discontinue their medication? Clin Pediatr (Phila) 2012;51:763-769.
Efron D, Jarman FC, Barker MJ. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. J Paediatr Child Health 1998;34:288-292.
A 14-month randomized clinical trial of treatment strategies for attention- deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56:1073-1086.
Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90.
Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003;42:424-433.
Kim BS, Park EJ. An observational multi-center study for evaluation of efficacy, safety and parental satisfaction of methylphenidate- OROS in children with ADHD. J Korean Acad Child Adolesc Psychiatry 2005;16:279-285.
Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008;28(3 Suppl 2):S46-S53.
Levy F, Wimalaweera S, Moul C, Brennan J, Dadds MR. Dopamine receptors and the pharmacogenetics of side-effects of stimulant treatment for attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2013;23:423-425.
McGough J, McCracken J, Swanson J, Riddle M, Kollins S, Greenhill L, et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45:1314-1322.
Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005;30:1374-1382.
Zeni CP, Guimaraes AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144B: 391-394.
Gruber R, Joober R, Grizenko N, Leventhal BL, Cook EH Jr, Stein MA. Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:233-239.
Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006; 60:1111-1120.
Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, Greenstein DK, et al. Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 2005;134B:67-72.
Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N, et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 2006;11:934-953.
Joung Y, Kim CH, Moon J, Jang WS, Yang J, Shin D, et al. Association studies of -3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population. Am J Med Genet B Neuropsychiatr Genet 2010;153B: 691-694.
Kim CH, Waldman ID, Blakely RD, Kim KS. Functional gene variation in the human norepinephrine transporter: association with attention deficit hyperactivity disorder. Ann N Y Acad Sci 2008; 1129:256-260.
Xu X, Knight J, Brookes K, Mill J, Sham P, Craig I, et al. DNA pooling analysis of 21 norepinephrine transporter gene SNPs with attention deficit hyperactivity disorder: no evidence for association. Am J Med Genet B Neuropsychiatr Genet 2005;134B:115-118.
Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1412-1418.
Yang L, Wang YF, Li J, Faraone SV. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 2004;43:1154-1158.
So YK, Noh JS, Kim YS, Ko SG, Koh YJ. The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc 2002;41:283-289.
Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J 2004;45:81-89.
Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184-192.
Bruss M, Kunz J, Lingen B, Bonisch H. Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Hum Genet 1993;91:278-280.
Cho SC, Kim BN, Cummins TD, Kim JW, Bellgrove MA. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. J Psychopharmacol 2012;26:380-389.
Kim CH, Kim HS, Cubells JF, Kim KS. A previously undescribed intron and extensive 5’ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem 1999;274:6507-6518.
Karabekiroglu K, Yazgan YM, Dedeoglu C. Can we predict shortterm side effects of methylphenidate immediate-release? Int J Psychiatry Clin Pract 2008;12:48-54.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.